Andreessen Horowitz (a16z)General Partner, Bio + Health
Jun 2017 — Present
Invests in biotechnology and healthcare. Board roles include Asimov, Cartography, Dyno, Earli, Komodo Health, and Octant Bio.
Jorge Conde invests in therapeutics, diagnostics, life-sciences tools, and healthcare software as a general partner at Andreessen Horowitz.
Jorge Conde invests in therapeutics, diagnostics, life-sciences tools, and healthcare software as a general partner at Andreessen Horowitz.
Career
Syros PharmaceuticalsChief Strategy Officer, Chief Financial Officer and Chief Product Officer
Apr 2016 — Mar 2017
Held strategy, finance, and product leadership roles at a biotechnology company developing medicines through gene regulation.
KnomeCo-founder and Chief Executive Officer
2007 — 2015
Co-founded and led the human-genome interpretation company through its acquisition by Tute Genomics in 2015.
MedImmuneMarketing and Operations Manager
2006 — 2007
Worked in strategic marketing and operations.
Flagship VenturesLife Sciences Summer Associate
2005 — 2005
Morgan StanleyBiotechnology Investment Banker
2000 — 2003
Advised biotechnology and genomics companies.
Cosigns Received
Featured Media
youtube.com
Shifting Risk Mindsets, from Tech to Bio
a16z.simplecast.com
Inside Moderna’s Personalized Cancer Vaccine
a16z.com
The Next Bio Startup: Born in the Wild vs. Bred in Captivity
Conde's 2019 founder account links Knome's early genomics work to his case for independently founded, engineering-driven biotech companies.
a16z.com
Operating on DNA is more like surgery than medicine
Conde proposes a new model for personalized gene editing, built around accredited treatment centers and reusable tools.